BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Independent Stock Specific Research

ECVT: Rearranging the Year, Not Cash Flow

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Equity Bottom-Up

<ul>
<li>ECVT continues to experience setbacks to its operations this year. The latest from its joint venture, Zeolyst, having renewable fuel customers delay catalyst orders.   </li>
<li>The headwinds ECVT has dealt with in the past year creates pressure on investor sentiment and the Company now having to reassure investors it can sustain generating free cash flow.</li>
<li>The investor story that shifted out to 2025 remains unchanged. We believe ECVT’s stock price currently reflects investor unrest as to the possibility of ECVT’ 2025 prospects.  </li>
</ul>


ECVT continues to experience setbacks to its operations this year. The latest from its joint venture, Zeolyst, having renewable fuel customers delay catalyst orders.   
The headwinds ECVT has dealt with in the past year creates pressure on investor sentiment and the Company now having to reassure investors it can sustain generating free cash flow.
The investor story that shifted out to 2025 remains unchanged. We believe ECVT’s stock price currently reflects investor unrest as to the possibility of ECVT’ 2025 prospects.  


ECVT: Another Pushout in Story, PT to $12

Ecovyst

ECVT: Another Pushout in Story, PT to $12